Patient cohort.

*Patient underwent OLT prior to liver biopsy. HB, HBV co-infection; unl, upper normal limit; RE, relapse; RR, rapid response (HCV RNA (-) at 4�C5 weeks of therapy; SVR, sustained viral response (HCV RNA (-) for >24 weeks post therapy); ETR, HCV RNA (-) at end of therapy; UNL, upper normal level, ND, not done; NA, not applicable; GT, HCV genotype, VL, viral load; ALT, (serum) alanine aminotransferase; FIBR, fibrosis (scoring range: 0�C4 [31]), INFL, portal inflammation (scoring range 0�C4 [31]).*患者在接受肝活检前接受了原位肝移植（orthotopic liver transplantation, OLT）。HB：乙型肝炎病毒（hepatitis B virus, HBV）合并感染；unl：正常上限（upper normal limit）；RE：复发；RR：快速应答（治疗4~5周时HCV RNA转阴）；SVR：持续病毒学应答（治疗结束后HCV RNA转阴持续>24周）；ETR：治疗结束时HCV RNA转阴；UNL：正常上限（upper normal level）；ND：未行检测；NA：不适用；GT：丙型肝炎病毒（hepatitis C virus, HCV）基因型；VL：病毒载量（viral load）；ALT：（血清）丙氨酸氨基转移酶（alanine aminotransferase）；FIBR：肝纤维化（fibrosis，评分范围：0~4 [31]）；INFL：门脉炎症（portal inflammation，评分范围：0~4 [31]）